Gene‑editing firm Metagenomi announced a restructuring that cut roughly 25% of its staff, including the CEO, to focus resources on its preclinical hemophilia A program. The move accompanies new preclinical dose‑range data for MGX‑001 showing curative factor VIII (FVIII) activity in nonhuman primates. Metagenomi said the tactic is a deliberate pivot to prioritize the most advanced program amid capital constraints. The hemophilia NHP data suggest a durable, potentially one‑time corrective effect; the company’s narrower operating footprint and leadership changes underscore the high‑stakes tradeoff between advancing preclinical assets and maintaining broader discovery portfolios.